JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Copyright © 2019 Elsevier B.V. All rights reserved..
Cytokines play a central role in the pathophysiology of autoimmune and inflammatory diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized as a major target to inhibit the effect of a wide array of cytokines. JAK inhibitors are increasingly used in the setting of inflammatory and autoimmune diseases. While the currently approved drugs are panJAK inhibitors, more selective small molecules are being developed and tested in various rheumatic disorders. In this extensive review, we present evidence- or hypothesis-based perspectives for these drugs in various rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, and autoinflammatory diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 18(2019), 11 vom: 15. Nov., Seite 102390 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jamilloux, Yvan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Inflammatory Agents |
|---|
| Anmerkungen: |
Date Completed 08.11.2019 Date Revised 08.11.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2019.102390 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301292531 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301292531 | ||
| 003 | DE-627 | ||
| 005 | 20231225104326.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2019.102390 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1004.xml |
| 035 | |a (DE-627)NLM301292531 | ||
| 035 | |a (NLM)31520803 | ||
| 035 | |a (PII)S1568-9972(19)30197-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jamilloux, Yvan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a JAK inhibitors for the treatment of autoimmune and inflammatory diseases |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2019 | ||
| 500 | |a Date Revised 08.11.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier B.V. All rights reserved. | ||
| 520 | |a Cytokines play a central role in the pathophysiology of autoimmune and inflammatory diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized as a major target to inhibit the effect of a wide array of cytokines. JAK inhibitors are increasingly used in the setting of inflammatory and autoimmune diseases. While the currently approved drugs are panJAK inhibitors, more selective small molecules are being developed and tested in various rheumatic disorders. In this extensive review, we present evidence- or hypothesis-based perspectives for these drugs in various rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, and autoinflammatory diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autoimmune disease | |
| 650 | 4 | |a JAK inhibitor | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Tofacitinib | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a El Jammal, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Vuitton, Lucine |e verfasserin |4 aut | |
| 700 | 1 | |a Gerfaud-Valentin, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Kerever, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Sève, Pascal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 18(2019), 11 vom: 15. Nov., Seite 102390 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:11 |g day:15 |g month:11 |g pages:102390 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2019.102390 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2019 |e 11 |b 15 |c 11 |h 102390 | ||